SAA MSCNCT07903649
A Randomized, Controlled Clinical Study on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Combined With Standard Immunosuppressants in the Treatment of Children With Severe Aplastic Anemia
StatusCompleted
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Complete response rate (CR) at 6 months of administration
Timeframe: From the start of treatment to the cessation of treatment for 6 months
Secondary (1)
Partial hematological response rate (PR) and total hematological response rate (OR) at 6 months of administration
Arms and interventions
Group AExperimental
Standard immunosuppressive (ATG/ALG)therapy for acquired severe aplastic anemia in children
Group BExperimental
Umbilical cord mesenchymal stem cells combined with standard immunosuppressants (UC-MSC+ATG/ALG) for the treatment of severe acquired aplastic anemia in children anemia
Other: Umbilical Cord Mesenchymal Stem Cells with ATG/ALG
Drugs: ATG/ALG
Sites
1 site in 1 country
- State key laboratory of experimental hematology,National clinical Research center for blood diseasesTianjin, Tianjin Municipality, China